Following on from the recommendations in the paper 'Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement', the ECMC Programme Office and the Health Research Authority have collaborated to produce a set of podcasts to inform and educate a range of stakeholders on the common questions around the management and delivery of CID trials. These podcasts have been designed for anyone with an interest in working on or reviewing CID trials. They are presented by experienced researchers, patients, ethic committee chair and members of the HRA.

Hear about Complex Innovative Design trials from the HRA’s perspective
Speaker: Will Navaie, Engagement Manager at the Health Research Authority

Podcast 8. Complex Innovative Design Trials And HRA Approval

Following on from the recommendations in the paper 'Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement', the ECMC Programme Office and the Health Research Authority have collaborated to produce a set of podcasts to inform and educate a range of stakeholders on the common questions around the management and delivery of CID trials. These podcasts have been designed for anyone with an interest in working on or reviewing CID trials. They are presented by experienced researchers, patients, ethic committee chair and members of the HRA.

Hear about how to write patient facing documents that make sense. You’ll hear recommendations on how information should be presented for patients and their family including the importance of considering the timing of sharing this information.
Speakers: Stephanie Ellis, Chair of Hampstead and Cambridge Central Ethics Committee and Debbie Keatley, Patient Representative from the Independent Cancer Patients’ Voice.

Podcast 7. How To Write Patient Facing Documents That Make Sense

Following on from the recommendations in the paper 'Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement', the ECMC Programme Office and the Health Research Authority have collaborated to produce a set of podcasts to inform and educate a range of stakeholders on the common questions around the management and delivery of CID trials. These podcasts have been designed for anyone with an interest in working on or reviewing CID trials. They are presented by experienced researchers, patients, ethic committee chair and members of the HRA.

Hear about what ethics committee members need to know from applicants about CID trials.
Speaker: Stephanie Ellis, Chair of the Hampstead and Cambridge Central Ethics Committee

Podcast 6. What Do REC Members Need To Know About CID Trials

Following on from the recommendations in the paper 'Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement', the ECMC Programme Office and the Health Research Authority have collaborated to produce a set of podcasts to inform and educate a range of stakeholders on the common questions around the management and delivery of CID trials. These podcasts have been designed for anyone with an interest in working on or reviewing CID trials. They are presented by experienced researchers, patients, ethic committee chair and members of the HRA.

Hear about what information is important to patients and their families when considering taking part in a CID trial.
Speaker: Debbie Keatley, Patient Representative from the Independent Cancer Patients’ Voice.

Podcast 5. What Information Is Important To Patients And Their Families.

Following on from the recommendations in the paper 'Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement', the ECMC Programme Office and the Health Research Authority have collaborated to produce a set of podcasts to inform and educate a range of stakeholders on the common questions around the management and delivery of CID trials. These podcasts have been designed for anyone with an interest in working on or reviewing CID trials. They are presented by experienced researchers, patients, ethic committee chair and members of the HRA.

Hear about the transparency and publication of data when an arm in a CID trial closes.
Speaker: Professor Pam Kearns, Professor of Clinical Paediatric Oncology, Director of the Cancer Research UK Clinical Trials Unit and Institute of Genomic Sciences in Birmingham

Podcast 4. Transparency And Publication Of Finished Arm Data

Following on from the recommendations in the paper 'Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement', the ECMC Programme Office and the Health Research Authority have collaborated to produce a set of podcasts to inform and educate a range of stakeholders on the common questions around the management and delivery of CID trials. These podcasts have been designed for anyone with an interest in working on or reviewing CID trials. They are presented by experienced researchers, patients, ethic committee chair and members of the HRA.

Hear about what a Data Monitoring Committee does, why it is important and how it makes decisions about CID trials.
Speaker: Louise Brown

Podcast 3. What Is The Role Of The Data Monitoring Committee In CID Trials

Following on from the recommendations in the paper 'Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement', the ECMC Programme Office and the Health Research Authority have collaborated to produce a set of podcasts to inform and educate a range of stakeholders on the common questions around the management and delivery of CID trials. These podcasts have been designed for anyone with an interest in working on or reviewing CID trials. They are presented by experienced researchers, patients, ethic committee chair and members of the HRA.

Hear about what a ‘Complex Innovative Design (CID) trial is and why we should do them. You’ll hear examples of what is meant by a CID trial; the benefits of this method and the challenges they do pose.
Speaker: Professor Pam Kearns, Professor of Clinical Paediatric Oncology, Director of the Cancer Research UK Clinical Trials Unit and Institute of Genomic Sciences in Birmingham

Podcast 2. What Is A Complex Innovative Design And Why Do Them

Discussion on the development of the consensus statement for the design and conduct of Complex Innovative Design Trials.


Speaker - Sarah Blagden, Associate Professor of Experimental Cancer Therapeutics in the Department of Oncology, University of Oxford.

Podcast 9 - The development of the consensus statement for the design and conduct of CID Trials

Discussion on the statistical challenges and opportunities of defining, designing and analysing CID Trials.

Speaker - Catey Bunce, Reader in Medical Statistics, School of Population Health & Environmental Sciences, Faculty of Life Sciences and Medicine, King’s College London.

Podcast 10 - Defining, Designing and Analysing CID Trials

Discussion around the definition of a Platform Trials in Clinical Oncology and its advantages.

Speaker: David Sebag-Montefiore, Clinical oncologist at the  University of Leeds and Clinical Director Leeds Cancer Research Centre.

Podcast 11 - Defining a Platform trial and the advantages of using a platform trial design

NHS Health Research Authority

Related tracks